Show simple item record

dc.contributor.authorMervin, Merehau C
dc.contributor.authorLowe, Anthony
dc.contributor.authorGardiner, Robert A
dc.contributor.authorSmith, David P
dc.contributor.authorAitken, Joanne
dc.contributor.authorChambers, Suzanne K
dc.contributor.authorGordon, Louisa G
dc.date.accessioned2017-08-15T00:03:55Z
dc.date.available2017-08-15T00:03:55Z
dc.date.issued2017
dc.identifier.issn1743-7555
dc.identifier.doi10.1111/ajco.12663
dc.identifier.urihttp://hdl.handle.net/10072/344152
dc.description.abstractObjective: To estimate costs on the Medicare Benets Schedule (MBS) and the Pharmaceutical BenetsScheme (PBS) attributable to the diagnosis and treatment of prostate cancer.Methods: We used data from a cohort study of 1064 men with localized prostate cancer recruited between2005 and 2007 by 24 urologists across 10 sites in Queensland, Australia (ProsCan). We estimated the MBSand PBS costs attributable to prostate cancer from the date of initial appointment to 12 months after d iagnosisin 2013 Australian dollars using a comparison group without prostate cancer. We used generalized linearmodeling to identify key determinants of higher treatment-related costs.Results: From the date of initial appointment to 12 months postdiagnosis, the average MBS costs attributableto prostate cancer were $9,357 (SD $191) per patient. These MBS costs were most sensitive to having privatehealth insurance and the type of primary treatment received. The PBS costs were higher in the control groupthan in the ProsCan group ($5,641 vs $1,924).Conclusions: The costs of treating and managing prostate cancer are high and these result in a substantialnancial burden for the Australian MBS. Costs attributable to prostate cancer appear to vary widely basedon initial treatment and these are likely to increase with the introduction of more expensive services andpharmaceuticals. There is a pressing need for better prognostic tools to distinguish between indolent andaggressive prostate tumors to reduce potential over treatment and help ease the burden of prostate cancer.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherWiley-Blackwell Publishing
dc.relation.ispartofpagefrom152
dc.relation.ispartofpageto159
dc.relation.ispartofissue3
dc.relation.ispartofjournalAsia-Pacific Journal of Clinical Oncology
dc.relation.ispartofvolume13
dc.subject.fieldofresearchOncology and carcinogenesis
dc.subject.fieldofresearchOncology and carcinogenesis not elsewhere classified
dc.subject.fieldofresearchcode3211
dc.subject.fieldofresearchcode321199
dc.titleWhat does it cost Medicare to diagnose and treat men with localized prostate cancer in the first year?
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Health, School of Medicine
gro.hasfulltextNo Full Text
gro.griffith.authorChambers, Suzanne K.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record